DexCom (DXCM)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$1.52 (-1.93%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of DexCom (DXCM)
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Key Insights

Critical company metrics and information
  • Share Price

    $77.72
  • Market Cap

    $30.36 Billion
  • Total Outstanding Shares

    390.60 Million Shares
  • Total Employees

    9,600
  • Dividend

    No dividend
  • IPO Date

    April 14, 2005
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.dexcom.com

Historical Stock Splits

If you bought 1 share of DXCM before June 13, 2022, you'd have 4 shares today.
Execution DateSplit Amount
June 13, 20224-for-1

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$-1.37 Billion
Net Cash Flow$-22.40 Million
Net Cash Flow, Continuing$-32.30 Million
Net Cash Flow From Investing Activities$511.10 Million
Net Cash Flow From Operating Activities$821.70 Million
Exchange Gains/Losses$9.90 Million
Net Cash Flow From Investing Activities, Continuing$511.10 Million
Net Cash Flow From Financing Activities, Continuing$-1.37 Billion
Net Cash Flow From Operating Activities, Continuing$821.70 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Revenues$3.95 Billion
Net Income/Loss Available To Common Stockholders, Basic$680.80 Million
Costs And Expenses$3.21 Billion
Income/Loss From Continuing Operations Before Tax$743.90 Million
Operating Income/Loss$628.00 Million
Income Tax Expense/Benefit$63.10 Million
Net Income/Loss$680.80 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Research and Development$549.00 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Average Shares$824.30 Million
Net Income/Loss Attributable To Parent$680.80 Million
Diluted Earnings Per Share$1.66
Income/Loss From Continuing Operations After Tax$680.80 Million
Cost Of Revenue$1.51 Billion
Benefits Costs and Expenses$3.21 Billion
Operating Expenses$1.81 Billion
Basic Earnings Per Share$1.74
Preferred Stock Dividends And Other Adjustments$0.00
Basic Average Shares$788.30 Million
Income Tax Expense/Benefit, Deferred$13.40 Million
Gross Profit$2.44 Billion
Selling, General, and Administrative Expenses$1.26 Billion

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Prepaid Expenses$62.50 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Non-current Assets$1.98 Billion
Current Liabilities$1.73 Billion
Other Current Assets$3.61 Billion
Equity$1.98 Billion
Other Current Liabilities$1.63 Billion
Noncurrent Liabilities$2.64 Billion
Assets$6.35 Billion
Inventory$586.30 Million
Liabilities And Equity$6.35 Billion
Intangible Assets$106.20 Million
Liabilities$4.37 Billion
Equity Attributable To Parent$1.98 Billion
Current Assets$4.26 Billion
Wages$105.80 Million
Noncurrent Assets$2.09 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to DexCom (DXCM)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.